Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
IST:MEDTR's Debt-to-EBITDA is ranked better than 85.05% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs IST:MEDTR: 0.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Debt-to-EBITDA Related Terms
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Debt-to-EBITDA Chart
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
IST:MEDTR vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a Debt-to-EBITDA of 0.18 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS. This is 56% below median its historical median of 0.41. Over the past decade, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Debt-to-EBITDA has ranged from 0.14 to 1.60. According to the industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #71 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 14.9%.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Debt-to-EBITDA too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Debt-to-EBITDA of 0.18 is 56% below median its 10-year median of 0.41. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 1.60. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.61. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 0.18 is 88.8% below this industry median. Based on the distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #71 out of 475 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #71 out of 475 companies for Debt-to-EBITDA. This places MEDITERA TIBBI MALZEMENAYI VE TICARET AS in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.61. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 0.18 is 88.8% below this benchmark. Historically, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's own Debt-to-EBITDA has ranged from 0.14 to 1.60 over the past decade. While the company's 10-year median is 0.41 vs. the industry median of 1.61, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.61, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Debt-to-EBITDA of 0.18 is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Debt-to-EBITDA is 0.18, which is 56% below median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺39.50, compared to a current price of ₺25.50 — trading 35.4% below its estimated fair value. The current Debt-to-EBITDA is 0.18, which is 56% below median its 10-year median of 0.41 and 88.8% below the Medical Devices & Instruments industry median of 1.61. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current Debt-to-EBITDA is 0.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued.
The current stock price of ₺25.50 is trading 35.4% below its estimated GF Value™ of ₺39.50.
GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.
Key valuation signals for IST:MEDTR:
Debt-to-EBITDA: 0.18 (56% below median its 10-year median of 0.41)
GF Value™: ₺39.50 vs. price of ₺25.50 (35.4% below fair value)
Industry Position: 88.8% below the Medical Devices & Instruments median (#71 of 475)
No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
80GF Score
Get the complete analysis for IST:MEDTR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:MEDTR has been successfully added to your 
